Review
doi: 10.1016/j.neuron.2004.07.023.
Clearing tau pathology with Abeta immunotherapy--reversible and irreversible stages revealed
Affiliations
- PMID: 15294135
- DOI: 10.1016/j.neuron.2004.07.023
Item in Clipboard
Review
Clearing tau pathology with Abeta immunotherapy--reversible and irreversible stages revealed
Neuron.
.
Free article
Abstract
The report by Oddo and colleagues in this issue of Neuron demonstrates for the first time that clearance of amyloid also results in the removal of early-stage tau pathology in mice that develop both amyloid plaques and neurofibrillary tangles (NFT), the two hallmark lesions of Alzheimer's disease (AD). This result supports a primary role for Abeta in AD etiology.
Copyright 2004 Cell Press
Comment on
-
Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome.Neuron. 2004 Aug 5;43(3):321-32. doi: 10.1016/j.neuron.2004.07.003. Neuron. 2004. PMID: 15294141
Similar articles
-
Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome.Neuron. 2004 Aug 5;43(3):321-32. doi: 10.1016/j.neuron.2004.07.003. Neuron. 2004. PMID: 15294141
-
[Treatment strategy of Alzheimer's disease: pause in clinical trials of Abeta vaccine and next steps].Brain Nerve. 2010 Jul;62(7):659-66. Brain Nerve. 2010. PMID: 20675870 Review. Japanese.
-
Neurobiology. Untangling Alzheimer's by paring plaques bolsters amyloid theory.Science. 2004 Aug 6;305(5685):762. doi: 10.1126/science.305.5685.762a. Science. 2004. PMID: 15297635 No abstract available.
-
Prefilament tau species as potential targets for immunotherapy for Alzheimer disease and related disorders.Curr Opin Immunol. 2009 Jun;21(3):359-63. doi: 10.1016/j.coi.2009.05.001. Epub 2009 May 30. Curr Opin Immunol. 2009. PMID: 19482462 Review.
-
[The lesions of Alzheimer's disease: which therapeutic perspectives?].Bull Acad Natl Med. 2008 Feb;192(2):303-18; discussion 318-21. Bull Acad Natl Med. 2008. PMID: 18819685 Review. French.
Cited by
-
Sex-related dimorphism in dentate gyrus atrophy and behavioral phenotypes in an inducible tTa:APPsi transgenic model of Alzheimer's disease.Neurobiol Dis. 2016 Dec;96:171-185. doi: 10.1016/j.nbd.2016.08.009. Epub 2016 Aug 26. Neurobiol Dis. 2016. PMID: 27569580 Free PMC article.
-
Current concepts in therapeutic strategies targeting cognitive decline and disease modification in Alzheimer's disease.NeuroRx. 2005 Oct;2(4):612-26. doi: 10.1602/neurorx.2.4.612. NeuroRx. 2005. PMID: 16489369 Free PMC article. Review.
-
Nasal vaccination with a proteosome-based adjuvant and glatiramer acetate clears beta-amyloid in a mouse model of Alzheimer disease.J Clin Invest. 2005 Sep;115(9):2423-33. doi: 10.1172/JCI23241. Epub 2005 Aug 11. J Clin Invest. 2005. PMID: 16100572 Free PMC article.
-
Is amyloid plaque imaging the key to monitoring brain pathology of Alzheimer's disease in vivo?Eur J Nucl Med Mol Imaging. 2004 Nov;31(11):1539-40. doi: 10.1007/s00259-004-1676-9. Epub 2004 Sep 15. Eur J Nucl Med Mol Imaging. 2004. PMID: 15372211 No abstract available.
-
Yokukansan inhibits neuronal death during ER stress by regulating the unfolded protein response.PLoS One. 2010 Oct 12;5(10):e13280. doi: 10.1371/journal.pone.0013280. PLoS One. 2010. PMID: 20967273 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
